Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced its earnings results on Tuesday, May, 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.05. View Zynerba Pharmaceuticals' Earnings History.

8 equities research analysts have issued 12 month target prices for Zynerba Pharmaceuticals' stock. Their forecasts range from $28.00 to $42.00. On average, they expect Zynerba Pharmaceuticals' share price to reach $32.25 in the next twelve months. View Analyst Ratings for Zynerba Pharmaceuticals.

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (3/29/2017)
• 2. Maxim Group analysts commented, "Cannabis-based therapies are starting to gain acceptance in the medical community with novel therapeutics in advanced clinical development." (2/23/2017)

Some companies that are related to Zynerba Pharmaceuticals include Karyopharm Therapeutics (KPTI), Adamas Pharmaceuticals (ADMS), Aquinox Pharmaceuticals (AQXP), Rigel Pharmaceuticals (RIGL), Tetraphase Pharmaceuticals (TTPH), Collegium Pharmaceutical (COLL), Neos Therapeutics (NEOS), Catalyst Pharmaceuticals (CPRX), Agile Therapeutics (AGRX), pSivida Corp. (PSDV), Galectin Therapeutics (GALT), Sophiris Bio (SPHS), Kalvista Pharmaceuticals (KALV), Lipocine (LPCN), Innocoll Holdings PLC (INNL), Juniper Pharmaceuticals (JNP), SCYNEXIS (SCYX) and Fibrocell Science (FCSC).

(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Zynerba Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Marshall Wace North America L.P. (3.54%), Vanguard Group Inc. (3.22%), Perceptive Advisors LLC (1.90%), Sphera Funds Management LTD. (0.76%), Granite Point Capital Management L.P. (0.75%) and MARSHALL WACE ASIA Ltd (0.62%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, Michael Rapp and Suzanne M Hanlon. View Institutional Ownership Trends for Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. View Insider Buying and Selling for Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Vanguard Group Inc., Sphera Funds Management LTD., Granite Point Capital Management L.P., MARSHALL WACE ASIA Ltd, Chartwell Investment Partners LLC, Iguana Healthcare Management LLC and Bluestein R H & Co.. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher and Michael Rapp. View Insider Buying and Selling for Zynerba Pharmaceuticals.

Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Zynerba Pharmaceuticals stock can currently be purchased for approximately $19.00.